THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., April 30, 2004 – Amgen (N), today announced that Enbrel® (etanercept) has been approved by the U.S. Food and Drug Ad ASDAQ: AMGN) and Wyeth ...

Eight months after bowing to FDA pressure to pull the original spot, Amgen has launched a revamped television ad for Enbrel (etanercept) that it says better explains the product’s psoriasis indication ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

Phase-III results for Eli Lilly’s experimental moderate-to-severe plaque psoriasis drug Ixekizumab hints at a possible brawl between the Indiana drugmaker and Amgen, if the FDA approves the drug.

April 15, 2004 — The U.S. Food and Drug Administration (FDA) has approved an intravenous formulation of pantoprazole sodium, a cardioverter defibrillator system, and a first-time generic for ribavirin ...

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in ...

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...

For yet another example of the trend toward teaching old drugs new tricks, check out Exhibit E for Enbrel. According to research released today, the anti-rheumatoid arthritis med has shown an amazing ...

In November 2000, Immunex (Seattle, WA) initiated a patient enrollment program designed to increase year-end sales of its anti-inflammatory drug Enbrel. Immunex claims the program was implemented ...